
USD
$0.00
(0.00%
)At Close (As of Dec 12, 2025)
$116.87M
Market Cap
-
P/E Ratio
-0.23
EPS
$1.29
52 Week High
$0.55
52 Week Low
HEALTHCARE
Sector
| Field | Value (USD) |
|---|---|
| Gross Profit | -$17K |
| Total Revenue | $0 |
| Cost Of Revenue | $17K |
| Costof Goods And Services Sold | $17K |
| Operating Income | -$28M |
| Selling General And Administrative | $14M |
| Research And Development | $14M |
| Operating Expenses | $28M |
| Investment Income Net | - |
| Net Interest Income | $4.1M |
| Interest Income | $4.1M |
| Interest Expense | - |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $17K |
| Income Before Tax | -$26M |
| Income Tax Expense | - |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$26M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$28M |
| Ebitda | -$28M |
| Net Income | -$26M |
| Field | Value (USD) |
|---|---|
| Gross Profit | -$17K |
| Total Revenue | $0 |
| Cost Of Revenue | $17K |
| Costof Goods And Services Sold | $17K |
| Operating Income | -$28M |
| Selling General And Administrative | $14M |
| Research And Development | $14M |
| Operating Expenses | $28M |
| Investment Income Net | - |
| Net Interest Income | $4.1M |
| Interest Income | $4.1M |
| Interest Expense | - |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $17K |
| Income Before Tax | -$26M |
| Income Tax Expense | - |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$26M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$28M |
| Ebitda | -$28M |
| Net Income | -$26M |
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
Atossa Genetics Inc. is a clinical-stage biopharmaceutical company based in Seattle, Washington, focused on developing advanced therapies for breast cancer and infectious diseases. The company's robust pipeline includes innovative product candidates that address significant unmet medical needs in oncology, leveraging state-of-the-art drug delivery systems and novel formulations. By prioritizing enhanced patient outcomes through targeted therapies, Atossa stands at the forefront of pharmaceutical innovation, poised to make a meaningful impact in an evolving healthcare landscape.